Alzheimer's dementia: A brief review

Journal Medical Libanais

Volumn 60, Issue 4, 2012, Pages 192-199

  Bassil, Nazem ^a   Mollaei, Chirine ^a  

^a UNIVERSITY OF BALAMAND   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DONEPEZIL; GALANTAMINE; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIVASTIGMINE; SELEGILINE; TACRINE;

AGITATION; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ANOREXIA; CARDIOVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DELUSION; DEPRESSION; DIARRHEA; DIET; DISEASE COURSE; DIZZINESS; DOWN SYNDROME; DRUG DOSE TITRATION; DRUG FATALITY; GASTROINTESTINAL SYMPTOM; GENETIC RISK; HUMAN; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIINFARCT DEMENTIA; MUSCLE CRAMP; MUTATION; NAUSEA; NAUSEA AND VOMITING; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SMOKING;

ALZHEIMER DISEASE; HUMANS; RISK FACTORS;

MLCS; MLOWN;

EID: 84875621298     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. th edition, Washington, DC: American Psychiatric Association, 1994.
2. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer's disease. The Baltimore longitudinal study of aging. Neurology 2000; 54 (11): 2072-7.
3. Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology 2000; 55 (2): 198-204.
4. Ferri CP, Prince M, Brayne C et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 (9503): 2112-17.
5. Alzheimer's Association, fact sheet, March 2011, alz.org (Accessed January 4, 2012).
6. Evans DA. The epidemiology of dementia and Alzheimer's disease: an evolving field. J Am Geriatr Soc 1996; 44 (2): 1482-3.
7. van Duijn CM, Clayton D, Chandra V et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991; 20 suppl 2: S13-S20.
8. Silverman JM, Smith CJ, Marin DB, Mohs RC, Propper CB. Familial patterns of risk in very late-onset Alzheimer disease. Arch Gen Psychiatry 2003; 60 (2): 190-7.
9. Campion D, Dumanchin C, Hannequin D et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999; 65 (3): 664-60.
10. Sleegers K, Roks G, Theuns J et al. Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. Brain 2004; 127 (pt7): 1641-9.
11. Hsiung GY, Sadovnick AD. Genetics and dementia: risk factors, diagnosis and management. Alzheimers Dement 2007; 3: 418-27.
12. Li H, Wetten S, Li L et al. Candidate single-nucleotide polymorphisms from a genome wide association study of Alzheimer disease. Arch Neurol 2008; 65 (1): 45-53.
13. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol and misfolded proteins. Lancet 2004; 363 (9415): 1139-46.
14. Vanhanen M, Koivisto K, Moilanen L et al. Association of metabolic syndrome with Alzheimer disease: a populationbased study. Neurology 2006; 67 (5): 843-7.
15. Yaffe K, Kanaya A, Lindquist K et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292 (18): 2237-42.
16. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology 2003; 61 (12): 1667-72.
17. Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA. Current and remote blood pressure and cognitive decline. JAMA 1999; 281 (5): 438-45.
18. Kalmijn S, van Boxtel MP, Ocké M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004; 62 (2): 275-80.
19. Engelhart MJ, Geerlings MI, Ruitenberg A et al. Diet and risk of dementia. Does fat matter? : the Rotterdam Study. Neurology 2002; 59 (12): 1915-21.
20. Essink-Bot ML, Pereria J, Packer C, Schwarzinger M, Burstrom K. Cross-national comparability of burden of disease estimates: the European Disability Weights Project. Bull World Health Organ 2002; 80 (8): 644-52.
21. Rosengren A, Skoog I, Gustafson D, Wilhelmsen L. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 2005; 165 (3): 321-6.
22. Cournot M, Marquie JC, Ansiau D et al. Relation between body mass index and cognitive function in healthy middleaged men and women. Neurology 2006; 67 (7): 1208-14.
23. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 2000; 35 (12): 1305-12.
24. Morris MC, Evans DA, Bienias JL et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60 (7): 940-6.
25. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 1997; 145 (1): 33-41.
26. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer disease. Ann Neurol 2006; 59 (6): 912-21.
27. Schaefer EJ, Bongard V, Beiser AS et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006; 63 (11): 1545-50.
28. Morris MC, Evans DA, Tangney CC et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology 2006; 67 (8): 1370-6.
29. Foley DJ, White LR. Dietary intake of antioxidants and risk of Alzheimer disease: food for thought. JAMA 2002; 287 (24): 3261-3.
30. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nut 2000; 71 (2): 621S-629S.
31. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K. Acontrolled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative study. N Engl J Med 1997; 336 (17): 1216-22.
32. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142 (1): 37-46.
33. Larrieu S, Letenneur L, Helmer C, Dartigues JF, Barberger-Gateau P. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging 2004; 8 (3): 150-4.
34. Hassan A, Hunt BJ, O'Sullivan M et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004; 127 (pt 1): 212-19.
35. McMahon JA, Green TJ, Skeaff CM et al. Acontrolled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006; 354 (26): 2764-72.
36. Laugesen M, Fowles J. Scope for regulation of cigarette smoke toxicity according to brand differences in published toxicant emissions. N Z Med J 2005; 118: U1401.
37. Domino EF, Ni L, Xu Y et al. Regional cerebral blood flow and plasma nicotine after smoking tobacco cigarettes. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28 (2): 319-27.
38. Brody AL. Functional brain imaging of tobacco use and dependence. J Psychiatr Res 2006; 40 (5): 404-18.
39. Freund KM, Belanger AJ, D'Agostino RB, Kannel WB. The health risks of smoking. The Framingham Study: 34 years of follow-up. Ann Epidemiol 1993; 3 (4): 417-24.
40. Broe GA, Creasey H, Jorm AF et al. Health habits and risk of cognitive impairment and dementia in old age: a prospective study on the effects of exercise, smoking and alcohol consumption. Aust NZ J Public Health 1998; 22 (5): 621-3.
41. Poirier J, Delisle MC, Quirion R et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U SA 1995; 92 (26):12260-4.
42. Rafnsson SB, Deary IJ, Smith FB et al. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh artery study. J Am Geriatr Soc 2007; 55 (5): 700-7.
43. Weggen S, Eriksen JL, Das P et al. A subset of NSAIDs lower amyloidogenic Aß42 independently of cyclooxygenase activity. Nature 2001; 414 (6860): 212-16.
44. Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol 2008; 7 (1): 20-1.
45. Phaneuf S, Leeuwenburgh C. Apoptosis and exercise. Med Sc Sports Exerc 2001; 33 (3): 393-6.
46. Crawford JG. Alzheimer's disease risk factors as related to cerebral blood flow. Med Hypotheses 1996; 46 (4): 367-77.
47. Simonsick EM. Fitness and cognition: encouraging findings and methodological considerations for future work. J Am Geriatr Soc 2003; (51): 570-1.
48. Evans DA, Hebert LE, Beckett LA et al. Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch Neurol 1997; 54 (11): 1399-405.
49. Ngandu T, von Strauss E, Helkala EL et al. Education and dementia: what lies behind the association? Neurology 2007; 69 (14): 1442-50.
50. Wilson RS, Li Y, Aggarwal NT et al. Education and the course of cognitive decline in Alzheimer disease. Neurology 2004; 63 (7): 1198-202.
51. Wang HX, Karp A, Winblad B et al. Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen Project. Am J Epidemiol 2002; 155 (12): 1081-7.
52. Meeks TW, Ropacki SA, Jeste DV. The neurobiology of neuropsychiatric syndromes in dementia. Curr Opin Psychiatry 2006; 19 (6): 581-6.
53. Craig D, Hart DJ, McIlroy SP, Passmore AP. Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 19 (2-3): 154-7.
54. Hajjar RR. Psychosocial impact of urinary incontinence. Clinics in Geriatric Medicine 2004; 20: 553-64.
55. Perry EK, Tomlinson BE, Blessed G et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1457-9.
56. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000 Nov; 60 (5): 1095-122.
57. Trinh NH, Hoblyn J, Mohanty S et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003 Jan 8; 289 (2): 210-16.
58. Black SE, Doody R, Li H et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007 Jul 31; 69 (5): 459-69.
59. Harada CN, Shega JW, Sachs GA. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004 Dec 9; 351 (24): 2509-18.
60. Oertel W, Ross JS, Eggert K et al. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007; 69 Suppl. 1: S4-S9.
61. Rockwood K, Fay S, Song X et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ 2006; 174 (8): 1099-105.
62. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41 (10): 719-39.
63. Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998; 116: 331-47.
64. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24.